Frontier Capital Management Co. LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 236,935 shares of the biopharmaceutical company’s stock, valued at approximately $8,871,000.
Several other large investors have also made changes to their positions in ALNY. Royal Bank of Canada increased its stake in shares of Alnylam Pharmaceuticals by 63.0% in the second quarter. Royal Bank of Canada now owns 51,314 shares of the biopharmaceutical company’s stock worth $2,847,000 after buying an additional 19,827 shares in the last quarter. Public Employees Retirement System of Ohio increased its stake in shares of Alnylam Pharmaceuticals by 3.6% in the second quarter. Public Employees Retirement System of Ohio now owns 28,961 shares of the biopharmaceutical company’s stock worth $1,607,000 after buying an additional 1,000 shares in the last quarter. Calvert Investment Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 4,313 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 36 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $859,000. Finally, American Century Companies Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $577,000. 88.70% of the stock is owned by institutional investors and hedge funds.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded down 0.5909% during mid-day trading on Tuesday, reaching $45.3405. The company had a trading volume of 28,828 shares. The company’s 50-day moving average price is $40.56 and its 200-day moving average price is $51.95. Alnylam Pharmaceuticals, Inc. has a 52-week low of $31.38 and a 52-week high of $80.11. The company’s market capitalization is $3.89 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, February 8th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.02. The company had revenue of $17.50 million for the quarter, compared to analysts’ expectations of $10.66 million. Alnylam Pharmaceuticals had a negative net margin of 869.63% and a negative return on equity of 37.25%. The business’s quarterly revenue was up 130.3% compared to the same quarter last year. During the same period last year, the firm posted ($1.07) earnings per share. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.01) earnings per share for the current fiscal year.
This article was published by sleekmoney and is the sole property of of sleekmoney. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at http://sleekmoney.com/236935-shares-in-alnylam-pharmaceuticals-inc-alny-acquired-by-frontier-capital-management-co-llc/1660144.html.
A number of research analysts recently weighed in on the company. Vetr cut Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating and set a $41.90 target price on the stock. in a report on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $68.00 target price (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, February 9th. JMP Securities set a $69.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 3rd. Ladenburg Thalmann Financial Services assumed coverage on Alnylam Pharmaceuticals in a report on Thursday, February 2nd. They issued a “buy” rating and a $75.00 target price on the stock. Finally, Chardan Capital lifted their target price on Alnylam Pharmaceuticals from $69.00 to $97.00 and gave the company a “buy” rating in a report on Monday, January 9th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and an average target price of $62.83.
In related news, Director Philip A. Sharp sold 15,000 shares of the firm’s stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $37.83, for a total transaction of $567,450.00. Following the sale, the director now directly owns 155,795 shares in the company, valued at $5,893,724.85. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CMO Akshay Vaishnaw sold 29,165 shares of the firm’s stock in a transaction on Wednesday, November 30th. The stock was sold at an average price of $44.99, for a total transaction of $1,312,133.35. Following the sale, the chief marketing officer now owns 34,915 shares in the company, valued at $1,570,825.85. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 59,165 shares of company stock worth $2,448,833. 4.00% of the stock is currently owned by company insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/236935-shares-in-alnylam-pharmaceuticals-inc-alny-acquired-by-frontier-capital-management-co-llc/1660144.html
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.